drugset / Trial / NCT00689403

Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305

NCT00689403

Phase 1 Completed 50 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

To study the properties of different tablets/capsules of AZD1305 in healthy male volunteers.

Timeline

Start
2008-02
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1305 Small molecule Oral

Indications

No indication recorded.